Additionally, genetic modifications that incorporate surface-displayed ligands such as folate or epidermal growth factor receptor (EGFR)-targeting peptides have shown promising results in preclinical models by improving the selectivity and accumulation of EVs within the tumor microenvironment [29]. The gene discussed is EGFR; the disease is neoplasm.